{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T02:38:32Z","timestamp":1792636712192,"version":"4.5.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T00:00:00Z","timestamp":1785110400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T00:00:00Z","timestamp":1792627200000},"content-version":"vor","delay-in-days":87,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"DOI":"10.1186\/s12885-026-16556-4","type":"journal-article","created":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T11:25:43Z","timestamp":1785151543000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Effectiveness, safety, and retreatment outcomes in GEP-NET patients undergoing 177Lu-based PRRT: a ten-year real-world experience"],"prefix":"10.1186","volume":"26","author":[{"given":"Leonhard","family":"Trinkl","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Th\u00f6ne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josef","family":"Dierneder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Holger","family":"Rumpold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,27]]},"reference":[{"key":"16556_CR1","doi-asserted-by":"publisher","unstructured":"Niederle MB, Hackl M, Kaserer K, Niederle B. Gastroenteropancreatic neuroendocrine tumours: the current incidence and staging based on the WHO and European Neuroendocrine Tumour Society classification: an analysis based on prospectively collected parameters. Endocrine-Related Cancer. 2010;17:909\u201318. https:\/\/doi.org\/10.1677\/ERC-10-0152.\u00a0 Cited 2024 Feb 26.","DOI":"10.1677\/ERC-10-0152"},{"key":"16556_CR2","doi-asserted-by":"publisher","unstructured":"Baldelli R, Barnabei A, Rizza L, Isidori AM, Rota F, Di Giacinto P et al. Somatostatin Analogs Therapy in Gastroenteropancreatic Neuroendocrine Tumors: Current Aspects and New Perspectives. Front Endocrinol. 2014;5. https:\/\/doi.org\/10.3389\/fendo.2014.00007.\u00a0 Cited 2024 Jan 1.","DOI":"10.3389\/fendo.2014.00007"},{"key":"16556_CR3","doi-asserted-by":"publisher","unstructured":"Kwekkeboom DJ, De Herder WW, Kam BL, Van Eijck CH, Van Essen M, Kooij PP et al. Treatment With the Radiolabeled Somatostatin Analog 177Lu-DOTA-Octreotate: Toxicity, Efficacy, and Survival. JCO. 2008;26:2124\u201330. https:\/\/doi.org\/10.1200\/JCO.2007.15.2553.\u00a0 Cited 2023 Aug 24.","DOI":"10.1200\/JCO.2007.15.2553"},{"key":"16556_CR4","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1007\/s00259-013-2559-8","volume":"41","author":"A Romer","year":"2014","unstructured":"Romer A, Seiler D, Marincek N, Brunner P, Koller MT, Ng QKT, et al. Somatostatin-based radiopeptide therapy with [177Lu-DOTA]-TOC versus [90Y-DOTA]-TOC in neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2014;41:214\u201322. https:\/\/doi.org\/10.1007\/s00259-013-2559-8. Cited 2023 Aug 23.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"16556_CR5","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1007\/s00259-011-2039-y","volume":"39","author":"BLR Kam","year":"2012","unstructured":"Kam BLR, Teunissen JJM, Krenning EP, De Herder WW, Khan S, Van Vliet EI, et al. Lutetium-labelled peptides for therapy of neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2012;39:103\u201312. https:\/\/doi.org\/10.1007\/s00259-011-2039-y. Cited 2023 Aug 23.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"16556_CR6","doi-asserted-by":"publisher","unstructured":"Pavel M, De Herder WW. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors. Neuroendocrinology. 2017;105:193\u20135. https:\/\/doi.org\/10.1159\/000457957.\u00a0 Cited 2025 Oct 6.","DOI":"10.1159\/000457957"},{"key":"16556_CR7","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1056\/NEJMoa1607427","volume":"376","author":"J Strosberg","year":"2017","unstructured":"Strosberg J, El-Haddad G, Wolin E, Hendifar A, Yao J, Chasen B, et al. Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors. N Engl J Med. 2017;376:125\u201335. https:\/\/doi.org\/10.1056\/NEJMoa1607427. Cited 2024 Feb 29.","journal-title":"N Engl J Med"},{"key":"16556_CR8","doi-asserted-by":"publisher","unstructured":"Brabander T, Van Der Zwan WA, Teunissen JJM, Kam BLR, Feelders RA, De Herder WW et al. Long-Term Efficacy, Survival, and Safety of 177Lu-DOTA0,Tyr3octreotate in Patients with Gastroenteropancreatic and Bronchial Neuroendocrine Tumors. Clin Cancer Res. 2017;23:4617\u201324. https:\/\/doi.org\/10.1158\/1078-0432.CCR-16-2743.\u00a0 Cited 2024 Feb 1.","DOI":"10.1158\/1078-0432.CCR-16-2743"},{"key":"16556_CR9","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.ejca.2016.01.009","volume":"58","author":"D H\u00f6rsch","year":"2016","unstructured":"H\u00f6rsch D, Ezziddin S, Haug A, Gratz KF, Dunkelmann S, Miederer M, et al. Effectiveness and side-effects of peptide receptor radionuclide therapy for neuroendocrine neoplasms in Germany: A multi-institutional registry study with prospective follow-up. Eur J Cancer [Internet]. 2016;58:41\u201351. https:\/\/doi.org\/10.1016\/j.ejca.2016.01.009. Cited 2025 Oct 6.","journal-title":"Eur J Cancer"},{"key":"16556_CR10","doi-asserted-by":"publisher","first-page":"1857","DOI":"10.2967\/jnumed.112.119347","volume":"54","author":"A Sabet","year":"2013","unstructured":"Sabet A, Ezziddin K, Pape U-F, Ahmadzadehfar H, Mayer K, P\u00f6ppel T, et al. Long-Term Hematotoxicity After Peptide Receptor Radionuclide Therapy with Lu-Octreotate. J Nucl Med. 2013;54:1857\u201361. https:\/\/doi.org\/10.2967\/jnumed.112.119347. Cited 2024 Jan 1.","journal-title":"J Nucl Med"},{"key":"16556_CR11","doi-asserted-by":"publisher","first-page":"2486","DOI":"10.1007\/s00259-023-06166-8","volume":"50","author":"M Mitjavila","year":"2023","unstructured":"Mitjavila M, Jimenez-Fonseca P, Bell\u00f3 P, Pubul V, Percovich JC, Garcia-Burillo A, et al. Efficacy of 177Lu-DOTATATE in metastatic neuroendocrine neoplasms of different locations: data from the SEPTRALU study. Eur J Nucl Med Mol Imaging. 2023;50:2486\u2013500. https:\/\/doi.org\/10.1007\/s00259-023-06166-8. Cited 2025 Oct 6.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"16556_CR12","unstructured":"Poeppel TD, Boy C, Bockisch A, Kotzerke J, Buchmann I, Ezziddin S et al. DGN-Handlungsempfehlung (S1-Leitlinie) Peptid-Rezeptor-Radionuklid-Therapie (PRRT) somatostatinrezeptorexprimierender Tumore. Deutsche Gesellschaft f\u00fcr Nuklearmedizin, editor. 2013. [cited 2023 Aug 24]; https:\/\/www.nuklearmedizin.de\/leistungen\/leitlinien\/docs\/031-046_2017.pdf. Accessed 24 Aug 2023."},{"key":"16556_CR13","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","volume":"40","author":"ME Charlson","year":"1987","unstructured":"Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation. J Chronic Dis. 1987;40:373\u201383. https:\/\/doi.org\/10.1016\/0021-9681(87)90171-8. Cited 2024 Aug 4.","journal-title":"J Chronic Dis"},{"key":"16556_CR14","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1016\/j.annonc.2020.03.304","volume":"31","author":"M Pavel","year":"2020","unstructured":"Pavel M, \u00d6berg K, Falconi M, Krenning EP, Sundin A, Perren A, et al. Gastroenteropancreatic neuroendocrine neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals Oncol. 2020;31:844\u201360. https:\/\/doi.org\/10.1016\/j.annonc.2020.03.304. Cited 2023 Oct 14.","journal-title":"Annals Oncol"},{"key":"16556_CR15","doi-asserted-by":"publisher","first-page":"e13343","DOI":"10.1111\/jne.13343","volume":"35","author":"B Kos-Kud\u0142a","year":"2023","unstructured":"Kos-Kud\u0142a B, Casta\u00f1o JP, Denecke T, Grande E, Kjaer A, Koumarianou A, et al. European Neuroendocrine Tumour Society (ENETS) 2023 guidance paper for nonfunctioning pancreatic neuroendocrine tumours. J Neuroendocrinol. 2023;35:e13343. https:\/\/doi.org\/10.1111\/jne.13343. Cited 2025 Oct 8.","journal-title":"J Neuroendocrinol"},{"key":"16556_CR16","doi-asserted-by":"publisher","first-page":"1752","DOI":"10.1016\/S1470-2045(21)00572-6","volume":"22","author":"JR Strosberg","year":"2021","unstructured":"Strosberg JR, Caplin ME, Kunz PL, Ruszniewski PB, Bodei L, Hendifar A, et al. 177Lu-Dotatate plus long-acting octreotide versus high\u2013dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial. Lancet Oncol. 2021;22:1752\u201363. https:\/\/doi.org\/10.1016\/S1470-2045(21)00572-6. Cited 2023 Aug 23.","journal-title":"Lancet Oncol"},{"key":"16556_CR17","doi-asserted-by":"publisher","first-page":"2807","DOI":"10.1016\/S0140-6736(24)00701-3","volume":"403","author":"S Singh","year":"2024","unstructured":"Singh S, Halperin D, Myrehaug S, Herrmann K, Pavel M, Kunz PL, et al. [177Lu]Lu-DOTA-TATE plus long-acting octreotide versus high\u2013dose long-acting octreotide for the treatment of newly diagnosed, advanced grade 2\u20133, well-differentiated, gastroenteropancreatic neuroendocrine tumours (NETTER-2): an open-label, randomised, phase 3 study. Lancet. 2024;403:2807\u201317. https:\/\/doi.org\/10.1016\/S0140-6736(24)00701-3. Cited 2024 Nov 4.","journal-title":"Lancet"},{"key":"16556_CR18","doi-asserted-by":"publisher","first-page":"524","DOI":"10.2967\/jnumed.118.215376","volume":"60","author":"M Gabriel","year":"2019","unstructured":"Gabriel M, Nilica B, Kaiser B, Virgolini IJ. Twelve-Year Follow-up After Peptide Receptor Radionuclide Therapy. J Nucl Med. 2019;60:524\u20139. https:\/\/doi.org\/10.2967\/jnumed.118.215376. Cited 2023 Dec 31.","journal-title":"J Nucl Med"},{"key":"16556_CR19","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.2967\/jnumed.108.053421","volume":"50","author":"M Gabriel","year":"2009","unstructured":"Gabriel M, Oberauer A, Dobrozemsky G, Decristoforo C, Putzer D, Kendler D, et al. 68Ga-DOTA-Tyr Octreotide PET for Assessing Response to Somatostatin-Receptor\u2013Mediated Radionuclide Therapy. J Nucl Med. 2009;50:1427\u201334. https:\/\/doi.org\/10.2967\/jnumed.108.053421. Cited 2025 Aug 1.","journal-title":"J Nucl Med"},{"key":"16556_CR20","doi-asserted-by":"publisher","first-page":"726","DOI":"10.2967\/jnumed.124.268621","volume":"66","author":"FL Herr","year":"2025","unstructured":"Herr FL, Dascalescu C, Fabritius MP, Sheikh GT, Zacherl MJ, Wenter V, et al. PET- and CT-Based Imaging Criteria for Response Assessment of Gastroenteropancreatic Neuroendocrine Tumors Under Radiopharmaceutical Therapy. J Nucl Med. 2025;66:726\u201331. https:\/\/doi.org\/10.2967\/jnumed.124.268621. Cited 2026 Jan 29.","journal-title":"J Nucl Med"},{"key":"16556_CR21","doi-asserted-by":"publisher","unstructured":"Al-Toubah TE, Pelle E, Strosberg JR. Risk of myelodysplastic syndrome\/acute leukemia with sequential capecitabine\/temozolomide and 177Lu-dotatate. JCO. 2022;40:513\u2013513. https:\/\/doi.org\/10.1200\/JCO.2022.40.4_suppl.513.\u00a0 Cited 2026 Apr 22.","DOI":"10.1200\/JCO.2022.40.4_suppl.513"},{"key":"16556_CR22","doi-asserted-by":"publisher","first-page":"102141","DOI":"10.1016\/j.ctrv.2020.102141","volume":"93","author":"J Strosberg","year":"2021","unstructured":"Strosberg J, Leeuwenkamp O, Siddiqui MK. Peptide receptor radiotherapy re-treatment in patients with progressive neuroendocrine tumors: A systematic review and meta-analysis. Cancer Treat Reviews. 2021;93:102141. https:\/\/doi.org\/10.1016\/j.ctrv.2020.102141. Cited 2024 Jan 4.","journal-title":"Cancer Treat Reviews"},{"key":"16556_CR23","doi-asserted-by":"publisher","unstructured":"Delpassand ES, Yazdi SM, Ghantoji S, Nakasato A, Strickland C, Nunez R et al. Effectiveness and Safety of Retreatment with177Lu-DOTATATE in Patients with Progressive Neuroendocrine Tumors: A Retrospective Real-World Study in the United States. J Nucl Med. 2024;65:746\u201352. https:\/\/doi.org\/10.2967\/jnumed.123.265703.\u00a0 Cited 2025 Oct 9.","DOI":"10.2967\/jnumed.123.265703"},{"key":"16556_CR24","doi-asserted-by":"publisher","unstructured":"Sitani K, Parghane R, Talole S, Basu S. The efficacy, toxicity and survival of salvage retreatment PRRT with 177Lu-DOTATATE in patients with progressive NET following initial course of PRRT. BJR. 2022;95:20210896. https:\/\/doi.org\/10.1259\/bjr.20210896.\u00a0 Cited 2024 Jan 4.","DOI":"10.1259\/bjr.20210896"},{"key":"16556_CR25","doi-asserted-by":"publisher","unstructured":"Vaughan E, Machta J, Walker M, Toumpanakis C, Caplin M, Navalkissoor S. Retreatment with peptide receptor radionuclide therapy in patients with progressing neuroendocrine tumours: efficacy and prognostic factors for response. BJR. 2018;91:20180041. https:\/\/doi.org\/10.1259\/bjr.20180041.\u00a0 Cited 2024 Nov 7.","DOI":"10.1259\/bjr.20180041"},{"key":"16556_CR26","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1186\/s12885-019-6000-y","volume":"19","author":"S Rudisile","year":"2019","unstructured":"Rudisile S, Gosewisch A, Wenter V, Unterrainer M, B\u00f6ning G, Gildehaus FJ, et al. Salvage PRRT with 177Lu-DOTA-octreotate in extensively pretreated patients with metastatic neuroendocrine tumor (NET): dosimetry, toxicity, efficacy, and survival. BMC Cancer. 2019;19:788. https:\/\/doi.org\/10.1186\/s12885-019-6000-y. Cited 2025 Oct 31.","journal-title":"BMC Cancer"},{"key":"16556_CR27","unstructured":"National Cancer Institute (NCI). NET RETREAT: A Phase II Study of 177 Lutetium-DOTATATE Retreatment vs. Everolimus in Metastatic & Unresectable Midgut NET. clinicaltrials.gov; 2025 Jul. Report No.: NCT05773274. https:\/\/clinicaltrials.gov\/study\/NCT05773274. Accessed 1 Aug 2025."}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-026-16556-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-16556-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-16556-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T01:47:04Z","timestamp":1792633624000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-026-16556-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,27]]},"references-count":27,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["16556"],"URL":"https:\/\/doi.org\/10.1186\/s12885-026-16556-4","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,27]]},"assertion":[{"value":"29 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was conducted in accordance with the Declaration of Helsinki and the Good Clinical Practice (GCP) guidelines. Ethical approval was obtained from the Ethics Committee of the Johannes Kepler University Linz, local ethic number 1285\/2023, signed 20-11-2023. The requirement for informed consent was waived by the Ethics Committee due to the retrospective nature of the study and the use of pseudonymised data.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"1266"}}